Zontivity approved for people at high-risk of heart attack, stroke

May 8, 2014

(HealthDay)—Zontivity (vorapaxar) tablets have been approved by the U.S. and Drug Administration for people at high risk of heart attack or stroke.

The drug is the first in a new class called protease-activated receptor-1 antagonists, designed to weaken the tendency of platelets to clump and form a blood clot. But the agency said the drug increases users' risks of developing life-threatening bleeding. Zontivity's label includes a boxed warning describing this risk, the FDA said Thursday in a news release.

The drug is meant for people who have had a previous or blocked arteries in the arms or legs. It should not be used by people who have had a prior stroke, "mini-" or a prior episode of bleeding in the head, the agency warned.

The most common side effects include bleeding and bruising. Users who have these side effects should report them immediately to their doctors, the FDA advised.

Zontivity is made by Merck Sharp and Dohme Corp., whose parent Merck & Co. is based in Whitehouse Station, N.J.

Explore further: Merck blood thinner shows mixed results: study

More information: Visit the FDA to learn more.

Related Stories

Merck blood thinner shows mixed results: study

March 24, 2012

An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

Kcentra approved to stop severe bleeding in heart patients

April 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Opsumit approved for pulmonary arterial hypertension

October 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Northera approved for rare blood pressure condition

February 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Daily aspirin regimen not safe for everyone, FDA warns

May 6, 2014

(HealthDay)—Taking an aspirin a day can help prevent heart attack and stroke in people who have suffered such health crises in the past, but not in people who have never had heart problems, according to the U.S. Food and ...

Merck: New drugs pending approval or in late tests

May 6, 2014

Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others, company executives said Tuesday during a briefing on Merck's business.

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.